Rein Therapeutics (RNTX) Stock Price, News & Analysis

Company Overview

Rein Therapeutics, Inc. (NASDAQ:RNTX) is a clinical-stage biotechnology company focused on developing therapies for fibrotic diseases, including conditions affecting the lungs and other organs. The company’s research is aimed at addressing diseases in which abnormal tissue scarring can impair organ function and lead to serious, progressive health problems.

Rein Therapeutics’ lead development program is deupirfenidone, an investigational therapy being studied for idiopathic pulmonary fibrosis, a chronic lung disease characterized by progressive scarring of lung tissue. The company is evaluating the potential of deupirfenidone to provide a treatment option for patients with fibrotic disease.

The company is focused primarily on advancing its clinical development programs and establishing the safety and efficacy of its investigational therapies. As a clinical-stage biotechnology company, Rein Therapeutics’ products remain subject to clinical testing and regulatory review before they can be commercially marketed.

Key Stats

• Today's Range: $0.78 to $0.82
• 50-Day Range: $0.70 to $0.89
• 52-Week Range: $0.69 to $2.18
• Volume: 446,969 shs
• Average Volume: 436,194 shs
• Market Capitalization: $68.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Hold

Rein Therapeutics Stock Analysis - MarketRank™

Rein Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 451st out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Hold

Consensus Rating

Rein Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Rein Therapeutics has a consensus price target of $6.00, representing about 650.9% upside from its current price of $0.80.

Amount of Analyst Coverage

Rein Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Rein Therapeutics are expected to decrease in the coming year, from ($0.47) to ($0.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rein Therapeutics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rein Therapeutics is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.79% of the float of Rein Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Rein Therapeutics has a short interest ratio ("days to cover") of 1.41, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Rein Therapeutics has recently increased by 4.32%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rein Therapeutics does not currently pay a dividend.

Dividend Growth

Rein Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Rein Therapeutics has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Rein Therapeutics this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for RNTX on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rein Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.50% of the stock of Rein Therapeutics is held by insiders.

Percentage Held by Institutions

90.89% of the stock of Rein Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 10/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RNTX
• CIK: 1420565
• Web: www.reintx.com
• Phone: (737) 802-1989
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Rein Therapeutics: $6.00
• High Price Target: $8.00
• Low Price Target: $4.00
• Potential Upside/Downside: +660.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$49.87 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -63.69%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.27
• Quick Ratio: 4.27

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $0.05 per share
• Price / Cash Flow: 14.43
• Book Value: ($1.07) per share
• Price / Book: -0.74

Miscellaneous

• Outstanding Shares: 86,270,000
• Free Float: 84,973,000
• Market Cap: $68.04 million
• Optionable: N/A
• Beta: 1.35